Prostate Cancer

News and new technology innovations concerning how imaging technology can help diagnose and treat prostate cancer can be found on this channel.

UCLA investigators present the latest cancer research at the American Society of Clinical Oncology annual meeting June 2 to June 6 in Chicago
News | Radiation Oncology
Targeted Therapy for Early Breast Cancer, Progress Treating Recurrent Glioma, PSMA PET Scan Advances Research Presented

May 22, 2023 — Physicians and scientists from the UCLA Jonsson Comprehensive Cancer Center will discuss the latest ...

Time May 22, 2023
arrow
Cancer diagnotics company Paige has announced new advanced integration capabilities to the Paige Platform, a holistic web-based solution built for AI that enables complete digital pathology workflows and supports the evolving needs of modern labs.
News | Digital Pathology
Paige Introduces Advanced Integration Capabilities to its AI Digital Pathology Platform

May 18, 2023 — Paige, a global provider of end-to-end digital pathology solutions and clinical Artificial Intelligence ...

Time May 18, 2023
arrow
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 in recurrent prostate cancer
News | Prostate Cancer
Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

May 2, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of ...

Time May 02, 2023
arrow
AI-enhanced scanning provides a greater level of detail for MRI technologists and physicians.
Feature | Magnetic Resonance Imaging (MRI) | By Johnson Polakkal Joseph
MRI Meets AI

Magnetic resonance imaging (MRI) is a technology that has been around for more than four decades and is a staple in ...

Time May 01, 2023
arrow
The abstract data presented at American Urological Association's 2023 Annual Meeting indicates the AI-powered platform shows promise as a means of predicting extracapsular extension risk prediction, potentially improving treatment planning and patient outcomes
News | Prostate Cancer
Avenda Health’s Unfold AI Shown to More Precisely Predict Extraprostatic Extension Risk in Prostate Cancer Patients, Surpassing Conventional Methodology

April 27, 2023 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care ...

Time April 27, 2023
arrow
A supply problem with Pluvicto [177Lu-vipivotide tetraxetan; Novartis], the radiopharmaceutical used to treat metastatic prostate cancer, has led to shortages resulting in a delay of 3 months or longer for new patients
News | Radiopharmaceuticals and Tracers
Pluvicto Supply Shortage Update: What SNMMI is Doing

March 16, 2023 — A supply problem with Pluvicto [177Lu-vipivotide tetraxetan; Novartis], the radiopharmaceutical used to ...

Time March 16, 2023
arrow
18F-rhPSMA-7.3 PET image showing multiple areas of uptake in the prostate gland in a man with newly diagnosed prostate cancer Photo courtesy of Blue Earth Diagnostics
News | Prostate Cancer
Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 LIGHTHOUSE Study

February 9, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time February 09, 2023
arrow
Abhinav Jha to develop technique, test in patients with metastatic prostate cancer
News | Radiation Therapy
Imaging Technique May Measure Absorbed Dose from Radiation Therapy

December 22, 2022 — Patients with cancer that has spread to the bone are sometimes treated with alpha particle radiation ...

Time December 22, 2022
arrow
Artificial intelligence is used at the University of Pittsburgh Medical Center to support pathologists diagnosing prostate cancer
News | Digital Pathology
Ibex Deploys AI-powered Cancer Diagnostics Solution at UPMC

December 22, 2022 — Ibex Medical Analytics (Ibex), a leader in AI-powered cancer diagnostics, today announced the live ...

Time December 22, 2022
arrow
18F-rhPSMA-7.3 PET image showing multiple areas of uptake in the prostate gland in a man with newly diagnosed prostate cancer Photo courtesy of Blue Earth Diagnostics
News | Prostate Cancer
Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer

December 2, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time December 02, 2022
arrow
18F-rhPSMA-7.3 PET image showing prostate cancer spread beyond the prostate region (Photo courtesy of Blue Earth Diagnostics)
News | PET Imaging
Blue Earth Diagnostics Announces Results on Clinical Factors Impacting Detection Rates from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

November 2, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time November 02, 2022
arrow
Chad Tang, MD
News | Prostate Cancer
Metastasis-Directed Radiation Therapy Plus Hormone Therapy Improves Progression-Free Survival for Men with Advanced Prostate Cancer

October 27, 2022 — Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding ...

Time October 27, 2022
arrow
Randomized trial also finds addition of local treatment could offer patients more time off hormone therapy
News | Prostate Cancer
Radiation-hormone Therapy Combination May Slow Growth of Oligometastatic Prostate Cancer

October 25, 2022 — A new study offers a new option to patients with oligometastatic prostate cancer who want relief from ...

Time October 25, 2022
arrow
Evidence from VA medical centers nationwide supports benefits of prostate cancer screening
News | Prostate Cancer
Lower Prostate Cancer Screening Rates Associated with Subsequent Increase in Advanced Cancers

October 24, 2022 — In the face of conflicting evidence over the risks and benefits of routine prostate cancer screenings ...

Time October 24, 2022
arrow
Phase II trial suggests radiation could ward off complications of bone lesions and extend overall survival for patients with advanced cancers
News | Radiation Therapy
Radiation Therapy for High-risk, Asymptomatic Bone Metastases May Prevent Pain and Prolong Life

October 23, 2022 — Treating high-risk, asymptomatic bone metastases with radiation may reduce painful complications and ...

Time October 23, 2022
arrow
Phase III study provides randomized evidence of equivalent outcomes and side effects with 5 vs. 8 weeks of radiation for high-risk disease
News | Prostate Cancer
Shortened Course of Radiation Therapy Safe and Effective for Men with High-risk Prostate Cancer

October 23, 2022 — A new randomized study confirms that men with high-risk prostate cancer can be treated with five ...

Time October 23, 2022
arrow
News | PET Imaging
Blue Earth Diagnostics Announces FDA Acceptance of New Drug Application for 18F-rhPSMA-7.3, a Radiohybrid Prostate-Specific Membrane Antigen-Targeted PET Imaging Agent for Prostate Cancer

September 28, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time September 28, 2022
arrow
Precision cancer medicine is the goal of a new multidisciplinary team examining radiation therapy combined with immunotherapy
News | Prostate Cancer
Sylvester Game Changer Vehicle Among First in Nation to Offer Mobile Prostate Cancer Screening

September 26, 2022 — Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine’s Game ...

Time September 26, 2022
arrow
Hoag Memorial Hospital Presbyterian has been named a Radiopharmaceutical Therapy Center of Excellence (RTCoE) by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), a distinction held by only 17 centers in the U.S.
News | Radiology Business
Hoag Named Radiopharmaceutical Therapy Center of Excellence, Publishes Results of Breast and Prostate Cancer Trials

September 8, 2022 — Hoag Memorial Hospital Presbyterian has been named a Radiopharmaceutical Therapy Center of ...

Time September 08, 2022
arrow
Patients with detectable PSA (0.2-2.0 ng/mL) post-prostatectomy considered for salvage radiotherapy undergoing 18F-DCFPyl PSMA PET/CT staging. Image created by M.Ng et al, GenesisCare, Melbourne, Australia.
News | Prostate Cancer
New Research Shows PSMA PET/CT Imaging Changes Management for Close to 50% of Prostate Cancer Patients

September 8, 2022 — In prostate cancer patients experiencing recurrence following a radical prostatectomy, imaging with ...

Time September 08, 2022
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now